SD Biosensor

SD Biosensor FCF/Debt

The Free Cash Flow to Debt Ratio of SD Biosensor (137310.KS) as of Nov 2, 2026 is 86.50 %. In the previous year, Free Cash Flow to Debt Ratio was 12.90 % — a change of 570.63% (higher).

FCF/Debt

86.50 %

YoY

570.63%

Last updated:

Free Cash Flow to Debt Ratio of SD Biosensor is 2025 86.50 % . Free Cash Flow to Debt Ratio of SD Biosensor was 2024 12.90 % . It decreases by 570.63% higher compared to the previous year.

The SD Biosensor FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2019
-445.11 KRW
Jan 1, 2021
380,066.24 KRW
Jan 1, 2022
400,033.12 KRW
Jan 1, 2023
-83.80 KRW
Jan 1, 2024
12.90 KRW
Jan 1, 2025
86.50 KRW
The SD Biosensor FCF/Debt history
YEARFCF/DebtYoY
86.50 %+570.63%
12.90 %-115.39%
-83.80 %-100.02%
400,033.12 %+5.25%
380,066.24 %-85,487.86%
-445.11 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SD Biosensor Stock analysis

What does SD Biosensor do? SD Biosensor Inc generates revenue through the development and manufacturing of cholesterol and blood glucose testing equipment. The company sells rapid immunochemical diagnosis products, immunochemical fluorescence diagnosis products, molecular diagnosis products, and enzyme immunological reaction diagnosis products. These products are distributed domestically and internationally, targeting healthcare providers and consumers in the immunochemical, molecular, and point-of-care diagnosis sectors. The firm focuses on self blood glucose measurement and other diagnostic solutions for medical use. The company's product portfolio includes POCTs, which are used for point-of-care testing in medical settings. SD Biosensor Inc's offerings serve both the domestic market and overseas markets, with a strong emphasis on diagnostic equipment for healthcare applications. Their business model relies on the sale of these specialized medical devices to hospitals, clinics, and individual consumers seeking home health monitoring solutions. Revenue streams are derived from the research, development, and sale of diagnostic products, including immunochemical and molecular diagnosis tools. The firm's products are designed for use in clinical and self-testing environments, supporting both professional healthcare services and personal health management. SD Biosensor Inc's market segments include healthcare institutions and end-users requiring diagnostic testing for cholesterol, blood glucose, and other medical conditions. SD Biosensor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SD Biosensor stock

Free Cash Flow to Debt Ratio of SD Biosensor is 86.50 % in 2025.

Free Cash Flow to Debt Ratio of SD Biosensor changed from 12.90 % to 86.50 %, representing a 570.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio SD Biosensor since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's SD Biosensor with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — SD Biosensor

All Key Metrics — SD Biosensor